Key Takeaways Gilead's Trodelvy plus Keytruda cut disease progression or death risk by 35% in TNBC patients. The phase III ASCENT-04/KEYNOTE-D19 trial showed median PFS of 11.2 months vs 7.8 months with standard care GILD sees Trodelvy as a backbone therapy across first-line metastatic TNBC based on two phase III trials.Gilead Sciences, Inc. (GILD) announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study.Data from the phase III ASC ...